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ABSTRACT
Objectives: The purpose of the study was to compare detection rates (DR) of FMF-certified and non-certified biochemical 
tests (BC) in trisomy 21 screening at 11–13 + 6 weeks.
Material and methods: In 2267 singleton pregnancies FMF-certified doctors measured crown to rump length (CRL) and 
nuchal translucency (NT). Serum samples were tested for free β-hCG and the PAPP-A using 2 analysers (Delfia — Perkin 
Elmer and Immulite 2000 — DPC), the results were expressed in MoM values and used for computer calculation of the risk 
for trisomy 21. The cut-off value for the high trisomy 21 risk was 1:300. 
Results: Comparison of free β-hCG MoMs by DPC and Delfia demonstrated statistically significant differences in normal, 
and trisomy 21 fetuses respectively. Similarly, statistically significant differences were noted for PAPP-A MoMs. The above 
differences in MoMs resulted in altered sensitivity in screening for aneuploidy. The application of the FMF-certified method 
ensures a markedly higher DR = 74%, compared to non-certified tests (64%), both at 5% FPR.
The ROC analysis was performed in order to assess the efficacy of both tests. Results of trisomy 21 BC + NT risk scales us-
ing the Delfia and DPC methods are highly significant (p < 0.0001), which means that their discrimination ability is > 90%. 
The difference between results obtained using the Delfia and DPC methods is AUC = 0.0150 and is statistically significant 
(Z = 2.4728, p = 0.0134). 
Conclusions: The use of FMF-certified first trimester biochemistry analysers improves DR for trisomy 21. The use of 
non-certified analysers causes reduction of DR and an increase of invasive procedure rate.
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INTRODUCTION
Contemporary prenatal screening is based on ultra-
sound examinations and biochemical tests [1]. Many pro-
fessional societies and public healthcare organisation have 
accepted the trisomy 21 (Down syndrome) risk estimation 
model created by the Fetal Medicine Foundation (FMF). 
The FMF First Trimester Screening (FTS) scheme involves 
ultrasound assessment of fetal structures, biometric meas-
urements: Crown-Rump Length (CRL) and Nuchal Trans-
lucency (NT), along with first trimester biochemistry (BC) 
test. The latter, sometimes called “double test” is based 
on the levels of free β-hCG and pregnancy-associated 
plasma protein type A (PAPP-A) in maternal serum ex-
pressed as Multiple of the Median (MoM). BC test values 
and ultrasound measurements are analysed by appropri-
ate FMF-certified computer software to calculate patient 
individual risk for trisomy 21, 18 and 13 respectively (www.
fetalmedicine.org).
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This system assures high Detection Rate (DR) of approx. 
90%, with a relatively low False Positive Rate (FPR) leading 
to invasive testing rate of approx. 5% [2]. The efficacy of 
screening may be increased, with a simultaneous reduction 
of invasive testing rate, by addition of ultrasound markers 
of trisomy 21 (NB, DV PI, TR, FMA-angle) to the risk calcula-
tion algorithm. It should be noted that the use of additional 
markers should only be considered when the risk based on 
Maternal Age (MA), NT and the biochemistry test falls within 
the range of 1/50–1/1000 [3–6]. 
Addition of the first trimester biochemistry to the 
screening previously based on MA and NT increased DR 
substantially. In trisomy 21 there is a significant increase of 
free β-hCG level in maternal serum during the first and the 
second trimester. PAPP-A level increases throughout the 
whole duration of uncomplicated pregnancy. In trisomy 21 
PAPP-A level drops during the first trimester and in the 
second trimester appears normal or slightly reduced [1, 5]. 
Expressing free β-hCG and PAPP-A in MoMs allowed creating 
efficient risk calculation algorithm [7]. 
Maintenance of high standards of both ultrasound 
scan and first trimester biochemistry is crucial for the qual-
ity of screening. FMF provides training for physicians and 
sonographers that is concluded with a certificate for the 
11–14 weeks scan. The quality of the ultrasound scan is en-
sured by a system of yearly auditing. There is also a system 
of certification for first trimester biochemistry analysers. It 
should be noted that at present only three biochemistry 
analysers have the FMF certificate (manufactured by Perkin 
Elmer, Brahms, Roche). This ensures high DR (approx. 90%), 
with the acceptable ratio of indications for invasive testing 
(FPR — approx. 5%). The use of non-certified first trimester 
biochemistry analysers potentially can have a detrimental 
effect on the quality of screening.
OBJECTIVES
The purpose of the study was to compare DRs for tri-
somy 21 screening at 11–14 weeks of pregnancy, based on 
biochemical tests certified by the FMF (Delfia Express) and 
non-certified by the FMF (DPC — PRISCA).
MATERIAL AND METHODS
2267 fetuses from singleton pregnancies were scanned 
at 11–14 weeks between September 2006 and March 
2008. Physicians with valid FMF license measured CRL and 
NT. Ultrasound scans were performed using the Voluson Ex-
pert VE 730 equipment (General Electric). Maternal age and 
last menstrual period date were noted. Two blood samples, 
5 mL each, were collected from each patient. Serum samples 
(2 from each patient) were stored at –18ºC and later tested 
for free β-hCG and the PAPP-A level; using 2 methods: im-
munofluorescence (delayed fluorescence — Delfia — Perkin 
Elmer) and ELISA (enzyme-linked immunosorbent assay 
— Immulite 2000 — DPC). The results were later transformed 
into MoM values and used for computer calculation of the 
risk of trisomy 21 (FMF-certified Astraia software for Delfia 
and Prisca for Immulite). Considering the applied biochemi-
cal test methodology there were two study groups (DPC 
and Delfia). 
In both groups patients with trisomy 21 risk ≥ 1:300 were 
offered an invasive test (amniocentesis) for karyotyping. If 
the patient declined invasive testing, the karyotype was 
determined after birth, if the phenotype was suspicious for 
Down syndrome. The trisomy 21 status was determined for 
all patients. Based on the karyotype, patients were divided 
into two groups: normal karyotype and trisomy 21. Results 
were analysed with the statistical suite PQStat ver. 1.4.2.324.
The U Mann-Whitney test was used to compare the 
results for the trisomy 21 group with the results for the 
group with normal karyotype. The Wilcoxon test was used 
for comparison between results of Delfia and DPC.
The correlation between results of risk scores with 
a cut-off value of 1:300, and occurrence of trisomy 21 was 
analysed using the chi-squared test. The DR and the FPR 
were determined. Intra-class correlations were evaluated 
and Bland-Altman analyses were completed for risk results 
obtained for both methods: Delfia and DPC. ROC analyses 
were performed for BC only and BC + NT risk scores for Delfia 
and DPC respectively. The test probability at the level of 
p < 0.05 was accepted as significant. 
RESULTS
Comparison of test parameters is presented in the Ta-
ble 1. The biochemistry parameters were statistically signifi-
cantly different in the Delfia and in the DPC group, in relation 
to the karyotype. The only parameter, for which no statisti-
cally significant difference was found, was the free β-hCG 
level assayed using the DPC equipment and expressed in 
absolute values. Figures 1 and 2 show median distribution 
of risk scores in the T21 and no-T21 groups. 
The Bland-Altman analysis was applied in order to 
establish an intra-class correlation. A highly significant 
(p < 0.0001) intra-class correlations were found between 
results for the methods Delfia and DPC. In case of the trisomy 
21 BC risk the correlation was high = 0.895, and in case of the 
trisomy 21 BC + NT risk the inter-class correlation was even 
higher = 0.9905. For trisomy 21 BC risk results the variance 
coefficient was approx. 40%, and for the T21 BC + NT risk 
was lower = 13.29% (Figure 3). 
The ROC analysis was performed in order to assess 
the clinical efficacy of both tests (DPC BC + NT and Delfia 
BC + NT) in screening for trisomy 21 (Figures 4 and 5).
In case of the trisomy 21 BC risk scales for both the Delfia 
and the DPC methods, no significant (p > 0.05) discrimina-
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tion ability in relation to prediction of trisomy 21 was found. 
The difference between results obtained using the Delfia 
and the DPC methods is AUC = 0.0129 and it is not signifi-
cant (Z = 0.4798, p = 0.6314). However, the differences of 
trisomy 21 BC + NT risk scales using the Delfia and the DPC 
methods are highly significant (p < 0.0001), which means 
that their discrimination ability is high — over 90%. The dif-
ference between results obtained using the Delfia and the 
DPC methods is AUC = 0.0150 and is statistically significant 
(Z = 2.4728, p = 0.0134) (Table 2). 
DR values for different FPR for DPC and Delfia for com-
bined tests (NT + BC) are shown in Table 3.
DISCUSSION
Fetal Medicine Foundation screening for chromosomal 
defects with 11–14 wks scan with NT measurement and 
first trimester biochemistry test currently is a standard in 
many countries [8]. Polish Gynecological Society guide-
lines on prenatal diagnosis recommend application of both 
tests (first trimester biochemistry test and nuchal scan) at 
11–14 weeks of pregnancy [9]. 
There are very few publications regarding PAPP-A and 
free β-hCG levels in the Polish population. A limited num-
ber of FMF-certified analysers could be responsible for 
slow progress of introduction of first trimester biochem-
istry testing in Poland, where ELISA tests have been long 
used for assaying test substances. Despite a doubtless 
clinical value of the latter method, its inconsistency with 
FMF standards has to be stressed. The only available 
Table 1. Comparison of test parameters — normal karyotype and trisomy 21
Variable Trisomy 21 Mean SD Minimum Median Maximum U Mann-Whitney test
The risk of T21 BC NT Delfia
Yes 518.54 2649.96 2 27 24825 Z = –14.7550
No 9297 8608.9 2 6350 31399 p < 0.0001
The risk of T21 BC NT DPC
Yes 551.26 2756.89 2 27 24825 Z = –14.4523
No 9149.5 8577.59 2 6287 31399 p < 0.0001
β-hCG Delfia
Yes 56.59 32.84 2.3 51 167 Z = 2.0779
No 52.01 40.29 2.8 41.9 472.33 p = 0.0377
β-hCG DPC
Yes 58.45 36.43 2.1 50 167 Z = 1.5112
No 54.29 41.52 2.8 43.1 472.33 p = 0.1307
β-hCG — MoMs Delfia
Yes 1.67 0.95 0.2 1.33 4.36 Z = 2.9367
No 1.41 0.96 0.2 1.16 6 p = 0.0033
β-hCG — MoMs DPC
Yes 1.71 0.92 0.18 1.58 4.3 Z = 2.7562
No 1.47 0.98 0.18 1.2 6 p = 0.0058
PAPP-A Delfia
Yes 9.34 60.77 0.2 2.76 59.8 Z = –2.8417
No 4.11 4.43 0.31 3.11 60.45 p = 0.0045
PAPP-A DPC
Yes 3.2 2.38 0.19 2.78 13.1 Z = –2.0532
No 4.01 4.37 0.05 3.07 60.45 p = 0.0400
PAPP-A MoMs Delfia
Yes 1.18 1.1 0.16 0.77 4.49 Z = –3.7695
No 1.26 0.81 0.15 1.09 6 p = 0.0002
PAPP-A MoMs DPC
Yes 1.18 1.08 0.16 0.77 4.49 Z = –3.1758
No 1.24 0.8 0.15 1.08 6 p = 0.0015
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Figure 1. Median risk score distribution in the trisomy 21 (T21) and 
normal karyotype (unaffected) groups. It should be noted that both 
in the Delfia, and in the DPC group trisomy 21 risk values (calculated 
based on the BC + NT) are significantly increased compared to the 
healthy controls. That difference (healthy compared to trisomy 21) 
was not observed for the trisomy 21 risk calculated based on the BC 
only for the DPC and Delfia groups
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study comparing the ELISA-based method and methods 
FMF-certified is a paper by K. Spencer. The author proved 
that the use of a non FMF-certified analyser (DPC Immu-
lite 2000) leads to different results of biochemical tests 
than those obtained using FMF-certified equipment [10]. 
The mean free β-hCG MoM value in trisomy 21 was 1.703 for 
the DPC, compared to 1.698 for the analysis performed us-
ing FMF-certified Kryptor (Brahms) and the difference was 
not statistically significant. But the mean PAPP-A value in tri-
somy 21 measured using DPC was 0.62 MoM, compared to 
0.47 MoM in case of the analysis by Kryptor, and that differ-
ence was statistically significant (p = 0.025). Authors noticed 
that this affects sensitivity of the screening for trisomy 21. 
Screening based on DPC equipment ensured DR = 58% 
60
50
40
30
20
10
0
T2
1
un
a
ec
te
d
T2
1
un
a
ec
te
d
T2
1
un
a
ec
te
d
T2
1
un
a
ec
te
d
T2
1
un
a
ec
te
d
T2
1
un
a
ec
te
d
T2
1
un
a
ec
te
d
T2
1
un
a
ec
te
d
Dela DPC
β-hCG PAPP-A PAPP-A MoMβ-hCG MoM
Dela Dela DelaDPC DPCDPC
Figure 2. Median distributions of BC parameters in the trisomy 21 (T21) and normal karyotype 
(unaffected) groups. All study parameters were statistically significantly different in both groups
Figure 4. The ROC curve for the scale — the T21 BC + NT DPC risk
Figure 5. The ROC curve for the scale — the T21 BC + NT Delfia risk
Figure 3. The Bland-Altman graph for the variable — the T21 BC + NT risk
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with a 5% FPR, compared to DR = 62% for FMF-certified 
Kryptor analyser [10]. 
Similar results were obtained in our study. The free 
β-hCG DPC MoM range was 0.18–4.3, and free β-hCG Delfia 
MoM was 0.2–4.36 in normal babies. In trisomy 21 the range 
of free β-hCG DPC MoM was 0.18–6, and free β-hCG Delfia 
MoM was 0.2–6. Statistically significant differences were 
demonstrated for β-hCG MoM, and no such difference was 
found for the free β-hCG level expressed in absolute val-
ues. Similar statistically significant differences were noted for 
PAPP-A levels. The PAPP-A DPC MoM range for was (0.15–6) 
in trisomy 21 patients, and was the same in the PAPP-A Delfia 
MoM. For normal fetuses the PAPP-A MoM ranges for DPC 
and Delfia were identical: 0.16–4.49. 
In our study the differences between both methods in 
BC results expressed in MoMs significantly influenced sensi-
tivity of screening for chromosomal defects, similarly to the 
study by Spencer et al. [10]. DRs for trisomy 21 at various 
FPR are presented in the Table 3. Those results clearly indi-
cate that in each case the application of the FMF-certified 
method (Delfia) ensures a markedly higher DR compared 
to non-certified tests (DPC). At 5% FPR in the FMF-certified 
method the DR is 10% better. 
ROC graphs illustrate that both test methods offer sig-
nificant discrimination abilities, with some preponderance 
of the FMF-certified. 
The FMF-certified BC test provides a significantly higher 
DR for trisomy 21, with a potentially lower FPR; hence lower 
number of invasive procedures.
CONCLUSIONS
The use of FMF-certified analysers for the first trimester 
biochemistry in the combined test improves DR in screen-
ing for trisomy 21.
The use of non-certified analysers for first trimester bio-
chemistry decreases DR of the combined test and causes 
an increased invasive procedures rate.
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